ArticleDiscover oncology2026
Spatial transcriptomics of urothelial carcinoma with basal/squamous differentiation identifies Galectin-7 as a specific marker of squamous lineage commitment.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Urothelial carcinoma (UC) with basal/squamous (Ba/Sq) differentiation is an aggressive subtype associated with chemoresistance and poor prognosis. However, reliable biomarkers for its diagnosis remain limited, and current evaluation largely relies on morphology and p63 immunostaining, which lacks specificity. Using high-resolution spatial transcriptomics, we characterized the molecular continuum underlying Ba/Sq differentiation within UC and validated the findings by immunohistochemistry (IHC) in independent Ba/Sq UC and pure UC cohorts. Functional assays were performed in squamous carcinoma cell lines to assess the role of Galectin-7, a transcriptional target of p63, in cellular proliferation. Spatial analysis revealed a stromal–epithelial signaling axis driving Ba/Sq differentiation within UC, with NGFR-positive basal-like cells inducing Galectin-7 expression during early squamous commitment. Galectin-7 was absent in UC regions but strongly expressed in Ba/Sq-differentiated tumor nests. Its knockdown suppressed squamous carcinoma cell proliferation, supporting a functional role in tumor survival. Immunohistochemical analysis confirmed markedly higher specificity of Galectin-7 (92.2%) compared with p63 (12.5%), while maintaining high sensitivity (89.3% vs. 100%). Galectin-7 positivity was also associated with poorer progression-free survival, indicating its dual diagnostic and prognostic value. This study proposes a molecular and spatial framework for Ba/Sq differentiation within UC and identifies Galectin-7 as a specific diagnostic and prognostic marker, offering potential as a therapeutic target in Ba/Sq UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.